Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation.
Oda N, Miyahara N, Taniguchi A, Morichika D, Senoo S, Fujii U, Itano J, Gion Y, Kiura K, Kanehiro A, Maeda Y. Oda N, et al. Among authors: itano j. Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L407-L417. doi: 10.1152/ajplung.00386.2018. Epub 2019 Jan 3. Am J Physiol Lung Cell Mol Physiol. 2019. PMID: 30604629 Free article.
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network. Ninomiya K, et al. Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6. Chest. 2019. PMID: 31072612
Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: itano j. Acta Oncol. 2020 Mar;59(3):324-328. doi: 10.1080/0284186X.2019.1679880. Epub 2019 Oct 25. Acta Oncol. 2020. PMID: 31650873 No abstract available.
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H, Miyahara N, Taniguchi A, Senoo S, Itano J, Watanabe H, Oda N, Kayatani H, Ichikawa H, Shibayama T, Kajimoto K, Tanimoto Y, Kanehiro A, Maeda Y, Kiura K; OKAYAMA respiratory disease study group (ORDSG). Higo H, et al. Among authors: itano j. Respir Investig. 2020 May;58(3):185-189. doi: 10.1016/j.resinv.2019.12.007. Epub 2020 Feb 23. Respir Investig. 2020. PMID: 32102769 Free article.
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S, Miyahara N, Taniguchi A, Oda N, Itano J, Higo H, Hara N, Watanabe H, Kano H, Suwaki T, Fuchimoto Y, Kajimoto K, Ichikawa H, Kudo K, Shibayama T, Tanimoto Y, Kuyama S, Kanehiro A, Maeda Y, Kiura K; Okayama Respiratory Disease Study Group (ORDSG). Senoo S, et al. Among authors: itano j. PLoS One. 2020 Aug 27;15(8):e0236935. doi: 10.1371/journal.pone.0236935. eCollection 2020. PLoS One. 2020. PMID: 32853277 Free PMC article.
Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: itano j. Asia Pac J Clin Oncol. 2021 Feb;17(1):101-108. doi: 10.1111/ajco.13423. Epub 2020 Sep 3. Asia Pac J Clin Oncol. 2021. PMID: 32885583 Clinical Trial.
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S, Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M. Araki K, et al. Among authors: itano j. J Mol Med (Berl). 2021 Jan;99(1):131-145. doi: 10.1007/s00109-020-02001-x. Epub 2020 Nov 9. J Mol Med (Berl). 2021. PMID: 33169236 Free article.
52 results